Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility
January 07, 2019 18:35 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder
January 07, 2019 06:00 ET
|
Axsome Therapeutics, Inc.
Demonstrated statistically significant improvement in MADRS scores compared to active comparator (p<0.001 on primary endpoint) Rapid improvement in depressive symptoms demonstrating statistically...
Axsome Therapeutics Provides Year End 2018 Clinical Update
December 27, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
FDA clearance of IND received for Phase 2 trial of AXS-12 in narcolepsy Phase 2 results of AXS-05 in major depressive disorder on track for early January 2019 Phase 3 results of AXS-05 in treatment...
Axsome Therapeutics to Present at Biotech Showcase 2019
December 18, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
December 10, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
IDMC recommends continuation of trial evaluating AXS-05 versus placebo in Alzheimer’s disease agitation IDMC recommends no further enrollment to single-agent bupropion arm NEW YORK, Dec. 10, 2018 ...
Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder
November 14, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
November 09, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
Final Phase 3 results of AXS-05 in treatment resistant depression now anticipated in 1Q 2019 Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018 Phase 2/3...
Axsome Therapeutics to Report Third Quarter 2018 Financial Results on November 9, 2018
November 01, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Friday, November 9, 2018 at 8:00 AM Eastern Time NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation
October 18, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation
September 19, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...